CLDX — Celldex Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.27bn
- $1.55bn
- $1.55m
Brief: Celldex Therapeutics Q3 EPS USD -0.81
Celldex Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Celldex Therapeutics Q2 EPS USD -0.65
Celldex Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Celldex Announces First Patient Dosed In Phase 2 Study Of Barzolvolimab In Eosinophilic Esophagitis
Brief: Celldex Therapeutics Presents Positive Data From Barzolvolimab Chronic Urticaria Program At Eaaci 2023
Brief: Celldex Announces First Patient Dosed In Phase 1 Study Of Cdx-585 In Patients With Advanced Malignancies
Brief: Celldex Therapeutics Presents Positive Preclinical Data From TSLP/SCF Bispecific Antibody Program CDX-622 At Immunology2023
Celldex Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Celldex Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview
Big pharma interest in immunology sector to grow in near to medium term - Jefferies
Brief: Celldex Therapeutics Inc Plans To Continue To Develop Barzolvolimab For PN
Brief: Celldex Reports Fourth Quarter And Year End 2022 Financial Results And Provides Corporate Update
Celldex Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Celldex Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview
Brief: Celldex Therapeutics Presents Positive Data From Barzolvolimab Phase 1b Study In Chronic Inducible Urticaria
Celldex Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Celldex Reports Third Quarter 2022 Financial Results
Celldex Therapeutics Inc expected to post a loss of 58 cents a share - Earnings Preview